Improving radiotherapy for cervical cancer patients
Official title: Plan-of-the-day Radiotherapy for Patients With Locally Advanced Cervical Cancer - a Prospective Randomized Controlled Trial (the POD-protocol)
Run by Oslo University Hospital · NCT05634681 · Data updated 2026-11-12
This study is testing a new daily approach to radiotherapy for patients with advanced cervical cancer to see if it can improve treatment results and reduce side effects.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | Women only |
| Enrollment | 190 (estimated) |
| Sponsor | Oslo University Hospital Academic / other |
| Drugs / interventions | radiation |
| Locations | 1 site (Oslo) |
| Status | Recruiting |
| Started | November 13, 2022 |
| Main results expected | December 31, 2026 |
| Study ends | December 31, 2032 |
| Registry record updated | December 2, 2022 |
| Trial ID | NCT05634681 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include adults over 18 with histologically confirmed cervical cancer at FIGO stage IB1-IVa who can understand and complete patient questionnaires.
✕Probably not a fit
Patients with distant metastasis, prior pelvic radiotherapy, or significant uncontrolled illnesses may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study aims to enhance the treatment outcomes for patients with locally advanced cervical cancer (LACC) by implementing a 'plan-of-the-day' approach to radiotherapy. The focus is on assessing the potential benefits of this method in reducing side effects during and after treatment. Eligible participants will receive either the standard treatment plan or the new plan-of-the-day intervention, with their experiences and side effects monitored throughout the process.
Why it matters
Potential benefit: If successful, this approach could lead to reduced side effects and improved quality of life for cervical cancer patients undergoing radiotherapy.
How similar studies have gone: While the specific 'plan-of-the-day' approach may be novel, similar studies have shown promise in optimizing radiotherapy protocols for various cancers.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Histologically confirmed cervical cancer eligible for definitve radiochemotherapy * FIGO stage IB1-IVa * Over 18 years * Speaks and understands Norwegian or English. * ECOG 0-2 * Histology: Squamous cell carcinoma, adenocarcinoma, adenosquamous carcinoma * Ability to understand and fill in patient questionnaires, and willing to sign a written informed consent * Large movers (LM), fundus movement ≥2,5 cm. Exclusion Criteria: * Evidence of distant metastasis. Suspicious paraaortic lymphnodes below the renal vessels is allowed if they are covered by the radiation field * Patients with previous surgery for their cervical cancer * Uncontrolled intercurrent somatic illness. * Psychiatric illness /social situations limiting study compliance * Prior radiotherapy to the pelvis * Patients who are pregnant or breastfeeding is excluded due to risk of teratogenic and abortifacient effects of radiotherapy and cisplatin, and the potential risk of adverse effect of nursing infants * Patients under current treatment for other invasive s except non-melanoma skin cancers * Nephrostomy * Patients with inflammatory bowel disease
Where it's running
-
Oslo University Hospital
Oslo, Norway Recruiting
Study contacts
- Principal investigator: Kjersti Bruheim, MD PhD — Oslo University Hospital
- Study coordinator: Kjersti Bruheim, MD PhD
- Email: uxkjuh@ous-hf.no
- Phone: +4723934000
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Shorter pelvic radiotherapy after surgery for cervical or endometrial cancer
A randomized study tests whether a shorter course of postoperative whole-pelvic radiotherapy can be as safe and effective as the standard longer schedule for women with cervical or endometrial cancer.
-
Late radiation side effects after postoperative IMRT and brachytherapy for cervical and endometrial cancer
This project will see how often and how severe late gastrointestinal and urinary side effects are in people with cervical or endometrial cancer who received postoperative IMRT and/or brachytherapy at Tata Memorial Hospital.
-
Comparing clinic-only versus clinic plus community outreach to offer HPV self-collection for cervical screening in women with HIV
This project will test whether adding community health worker outreach to clinic services helps more women living with HIV complete HPV self-collection for cervical screening.
-
Outcomes for Oligometastatic and Oligorecurrent Cervical Cancer
This registry will see if adding local treatments such as radiation or surgery to standard systemic therapy helps people with oligo‑metastatic or oligo‑recurrent cervical cancer live longer or avoid progression.
-
Hyaluronic acid gel spacer to protect nearby organs during cervical cancer radiation
This pilot tests a hyaluronic acid gel spacer (Barrigel) to see if it helps people with cervical cancer receiving chemoradiotherapy and brachytherapy by creating space between the tumor and nearby organs.
-
Short-course (hypofractionated) versus standard radiotherapy with cisplatin and brachytherapy for locally advanced cervical cancer in Uganda
This trial tests whether a shorter, higher-dose radiotherapy schedule plus cisplatin and brachytherapy works as well and causes no more serious side effects than the usual longer schedule for women in Uganda with stage IB3–IIIC cervical cancer.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.